[{"address1": "6 Liberty Square", "address2": "Suite 2382", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "857 837 3099", "website": "https://www.transcodetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert Michael Dudley", "age": 72, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 474392, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas A. Fitzgerald M.B.A.", "age": 71, "title": "CFO, VP of Administration & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 358138, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zdravka  Medarova Ph.D.", "age": 48, "title": "Co-Founder & CTO", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anna  Moore Ph.D.", "age": 61, "title": "Co-Founder, Scientific Advisor & Member of Scientific Advisory Board", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Duggan M.B.A., R.N.", "title": "Senior Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qiyong Peter Liu Ph.D.", "age": 59, "title": "VP of Drug Discovery & Chief Scientist", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alan  Freidman", "title": "Vice President of Investor & Client Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 5.0, "open": 4.51, "dayLow": 3.75, "dayHigh": 4.53, "regularMarketPreviousClose": 5.0, "regularMarketOpen": 4.51, "regularMarketDayLow": 3.75, "regularMarketDayHigh": 4.53, "beta": -0.392, "forwardPE": -6.047619, "volume": 290596, "regularMarketVolume": 290596, "averageVolume": 122147, "averageVolume10days": 113715, "averageDailyVolume10Day": 113715, "bidSize": 800, "askSize": 800, "marketCap": 2390546, "fiftyTwoWeekLow": 3.75, "fiftyTwoWeekHigh": 856.0, "fiftyDayAverage": 8.193, "twoHundredDayAverage": 84.463, "currency": "USD", "enterpriseValue": -4943943, "floatShares": 495536, "sharesOutstanding": 627440, "sharesShort": 10124, "sharesShortPriorMonth": 15930, "sharesShortPreviousMonthDate": 1701302400, "dateShortInterest": 1703808000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.01353, "heldPercentInstitutions": 0.12516, "shortRatio": 0.13, "shortPercentOfFloat": 0.0004, "impliedSharesOutstanding": 25097600, "bookValue": 16.617, "priceToBook": 0.22928326, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -19592604, "trailingEps": -652.0, "forwardEps": -0.63, "lastSplitFactor": "1:40", "lastSplitDate": 1705363200, "enterpriseToEbitda": 0.238, "52WeekChange": -0.99311775, "SandP52WeekChange": 0.21761274, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNAZ", "underlyingSymbol": "RNAZ", "shortName": "TransCode Therapeutics, Inc.", "longName": "TransCode Therapeutics, Inc.", "firstTradeDateEpochUtc": 1625837400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "09a0c637-96b3-3583-b5c0-c18005c44a45", "messageBoardId": "finmb_546709785", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.81, "targetHighPrice": 3.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 7452934, "totalCashPerShare": 14.833, "ebitda": -20765608, "totalDebt": 594694, "quickRatio": 1.331, "currentRatio": 1.674, "debtToEquity": 13.394, "returnOnAssets": -1.17377, "returnOnEquity": -3.0893202, "freeCashflow": -9583619, "operatingCashflow": -16430770, "financialCurrency": "USD", "trailingPegRatio": null}]